Sinopharm Group Co. Ltd (X2S) — Cash Flow Reinvestment Rate
Sinopharm Group Co. Ltd (X2S) has a Cash Flow Reinvestment Rate of 0.01x as of December 2022, reinvesting €767.58 Million (capex €654.69 Million plus investments €112.89 Million) from operating cash flow of €52.39 Billion. See Sinopharm Group Co. Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Sinopharm Group Co. Ltd Cash Flow Reinvestment Rate (2013–2025)
Historical reinvestment intensity for Sinopharm Group Co. Ltd across 13 annual periods. For the full cash flow conversion analysis, see Sinopharm Group Co. Ltd (X2S) cash conversion ratio.
Annual Cash Flow Reinvestment Rate for Sinopharm Group Co. Ltd (2013–2025)
Year-by-year capital reinvestment analysis for Sinopharm Group Co. Ltd. See Sinopharm Group Co. Ltd (X2S) flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.12x | €1.64 Billion | €14.14 Billion | €1.62 Billion | ▼ -32.2% |
| 2024 | 0.17x | €1.97 Billion | €11.55 Billion | €1.97 Billion | ▲ +24.4% |
| 2023 | 0.14x | €2.36 Billion | €17.17 Billion | €2.34 Billion | ▲ +32.2% |
| 2022 | 0.10x | €2.18 Billion | €20.96 Billion | €2.13 Billion | ▼ -53.5% |
| 2021 | 0.22x | €2.08 Billion | €9.31 Billion | €2.07 Billion | ▲ +29.9% |
| 2020 | 0.17x | €1.92 Billion | €11.15 Billion | €1.90 Billion | ▲ +39.4% |
| 2019 | 0.12x | €2.32 Billion | €18.78 Billion | €2.21 Billion | ▼ -87.9% |
| 2018 | 1.02x | €3.74 Billion | €3.65 Billion | €3.24 Billion | ▲ +18.9% |
| 2017 | 0.86x | €2.76 Billion | €3.21 Billion | €2.12 Billion | ▲ +168.3% |
| 2016 | 0.32x | €2.97 Billion | €9.26 Billion | €1.36 Billion | ▲ +321.2% |
| 2015 | 0.08x | €1.02 Billion | €13.41 Billion | €1.02 Billion | ▼ -71.4% |
| 2014 | 0.27x | €1.48 Billion | €5.56 Billion | €1.45 Billion | ▲ +10.3% |
| 2013 | 0.24x | €1.19 Billion | €4.94 Billion | €1.13 Billion | — |